(AOF) – Biosenic (+9.84% to 0.027 euros) is up sharply as it today announces the publication of data providing additional key indications for its main API (Active Pharmaceutical Ingredient), trioxide arsenic (ATO), in the treatment of systemic sclerosis (SSc), in an international peer-reviewed journal, “Arthritis Research & Therapy”. This biotech specializes in clinical trials in serious autoimmune and inflammatory diseases and cell therapy.
François Rieger, PhD, President and CEO of BioSenic declared: “These new preclinical data add to the multitude of in vitro and in vivo experimental data produced by BioSenic, by the entire scientific community and by industry. , which confirm the potential of arsenic salt-based drugs to rectify the pathophysiological parameters of the dysregulated immune system in a number of autoimmune diseases.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.